A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.
An electronic health record-integrated AI agent developed to improve patient education on prostate cancer with personalized ...
The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...
Early detection of prostate cancer can be life-saving — but determining whether the disease is localized or has spread requires a precise, multi-step evaluation. Here, Dr. Neha Maithel, medical ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the first patient enrollment in ...
Genetic testing, including germline and somatic, is vital for prostate cancer prognosis and personalized treatment strategies. PARP inhibitors, targeting BRCA mutations, are a promising therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results